Loading
Latest filing published 02 Mar 2022 for Kaleido Biosciences, Inc., €2,781.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by Vlieg Johan van Hylckama is known so far (2 March 2022): a share grant, €2,781, in Kaleido Biosciences, Inc. That is too little to draw conclusions. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration